Page 49 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine SUVmax relating to patient and tumor factors

forward stepwise regression model. These suggestions, Availability of data
in turn, could have enhanced the external validity of the
constructed model and also the identification of valid Supporting data is available from the corresponding author
predictors. Other limitations of this study include the on reasonable request.
lack of analysis of factors such as tumor size, which has References
shown some associations in various studies, along with
other factors such as hematological, biochemical, and 1. Budak E, Çok G, Akgün A, 2018, The contribution of
radiological parameters. fluorine 18F FDG PET/CT to lung cancer diagnosis, staging
and treatment planning. Mol Imaging Radionucl Ther,
5. Conclusion 27: 73–80.

Patient’s age and gender, as well as locations and stages https://doi.org/10.4274/mirt.53315
of their tumors, do not exhibit any particular association 2. Hu Y, Wu D, Tian C, et al., 2018, Diagnosis of multiple
with SUV , and any discernible trends are likely mere primary intestinal type adenocarcinoma in the lung by 18F
max
coincidences. On the contrary, there exists a potential FDG PET/CT. Clin Nucl Med, 43: 693–694.
correlation of SUV with histology, as evidenced in our https://doi.org/10.1097/RLU.0000000000002171
max
study, and with the grade of tumor differentiation, as 3. Goense L, Ruurda JP, Carter BW, et al., 2018, Prediction
described in various other studies. Further extensive studies and diagnosis of interval metastasis after neoadjuvant
with larger sample sizes are required and recommended to chemoradiotherapy for oesophageal cancer using 18F FDG
validate this finding. PET/CT. Eur J Nucl Med Mol Imaging, 45: 1742–17451.
Acknowledgments https://doi.org/10.1007/s00259-018-4011-6

None. 4. Farwell MD, Pryma DA, Mankoff DA, 2014, PET/
CT imaging in cancer: Current applications and future
Funding directions. Cancer, 120: 3433–3445.
None. https://doi.org/10.1002/cncr.28860
5. Annunziata S, Cuccaro A, Tisi MC, et al., 2018, FDG PET/CT
Conflict of interest at the end of immuno chemotherapy in follicular lymphoma:
The authors declare that they have no competing interests. The prognostic role of the ratio between target lesion and
liver SUVmax (rPET). Ann Nucl Med, 32: 372–377.
Author contributions https://doi.org/10.1007/s12149-018-1243-2
Conceptualization: Nishant Lohia, Sankalp Singh 6. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, et al., 2004,
Formal analysis: Sirshendu Ghosh, Indranil Sinha FDG-PET in staging lung cancer: How does it change the
Investigation: Abhishek Mahato, Dharmesh Paliwal, algorithm? Lung Cancer, 44: 175–181.
Nishant Lohia, Indranil Sinha, Gaurav Trivedi https://doi.org/10.1016/j.lungcan.2003.11.007
Methodology: Sankalp Singh, Sirshendu Ghosh
Writing—original draft: Nishant Lohia, Abhishek Mahato 7. Erdi YE, Macapinlac H, Rosenzweig KE, et al., 2000, Use
of PET to monitor the response of lung cancer to radiation
Writing—review & editing: Sankalp Singh, Dharmesh treatment. Eur J Nucl Med, 27: 861–866.
Paliwal
https://doi.org/10.1007/s002590000258
Ethics approval and consent to participate 8. Zheng D, Niu L, Liu W, et al., 2019, Relationship between

Ethics approval for the study was obtained from the the maximum standardized uptake value of fluoro-2-
Institutional Review Board of Command Hospital, deoxyglucose-positron emission tomography/computed
Lucknow (IEC/32/19). Written informed consent was tomography and clinicopathological characteristics in tongue
squamous cell carcinoma. J Can Res Ther, 15: 842–848.
obtained from all study participants for their inclusion in
the study. https://doi.org/10.4103/jcrt.JCRT_855_18
9. Sunnetcioglu A, Arısoy A, Demir Y, et al., 2015, Associations
Consent for publication between the standardized uptake value of (18)F-FDG PET/
A written informed consent was obtained from all study CT and demographic, clinical, pathological, radiological
participants for the use and publication of their clinical factors in lung cancer. Int J Clin Exp Med, 8: 15794–15800.
data without any identifying information about the 10. Liu S, Feng Z, Wen H, et al., 2018, FFDG PET/CT can
18
participants. predict chemosensitivity and proliferation of epithelial

Volume 1 Issue 2 (2024) 7 https://doi.org/10.36922/arnm.2032